相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2021)
Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study
W. Winn Chatham et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
Raj Tummala et al.
LUPUS SCIENCE & MEDICINE (2021)
Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2020)
The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method
Nobuyuki Yajima et al.
MODERN RHEUMATOLOGY (2020)
Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline
Kalliopi Klavdianou et al.
BIODRUGS (2020)
State-of-the-art treatment of systemic lupus erythematosus
Yoshiya Tanaka
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis
Irene B. Murimi-Worstell et al.
BMJ OPEN (2020)
Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study
Celine Miyazaki et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study
Diane Apostolopoulos et al.
LANCET RHEUMATOLOGY (2020)
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014)
April M. Jorge et al.
RHEUMATOLOGY (2018)
Systemic lupus erythematosus: nothing stale her infinite variety
Kenji Oku et al.
MODERN RHEUMATOLOGY (2018)
Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study
Yoshiya Tanaka et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2018)
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
Jeffrey M. Riggs et al.
LUPUS SCIENCE & MEDICINE (2018)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
Vera Golder et al.
ARTHRITIS RESEARCH & THERAPY (2017)
The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort
F. Conti et al.
LUPUS (2016)
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody
Li Peng et al.
MABS (2015)
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ian N. Bruce et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
Brandon W. Higgs et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN alpha antibody, in systemic lupus erythematosus
Yihong Yao et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies
AA Bengtsson et al.
LUPUS (2000)
分享论文
